About the drug : Angina pectoris, commonly known as angina, is the sensation of chest pain, pressure, or squeezing, often due to not enough blood flow to the heart muscle as a result of obstruction or spasm of the coronary arteries
Ranolazine which is currently approved by USFDA as an anti anginal agent reduces the Na-dependent Calcium overload via inhibition of the late sodium current (late I(Na)) and thus improves diastolic tone and oxygen handling during myocardial ischemia.
Ranolazine also has partial fatty acid oxidation inhibitory activites.
It shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation, oxidation of glucose requires less oxygen than the oxidation of fatty acid. Thus Ranolazine can help maintain myocardial function in times of ischemia